Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%

Clinical relapse · people with surgically‐induced remission in Crohn's disease

5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).

1 finding from 1 review

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASA changes endoscopic recurrence compared with purine antimetabolites (very low certainty).

1 finding from 1 review

Radiologic relapse · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASA changes radiologic relapse compared with purine antimetabolites (very low certainty).

1 finding from 1 review

Adverse events · people with surgically‐induced remission in Crohn's disease

5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).

1 finding from 1 review

Serious adverse events · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.3 [0.11, 0.8]
3 studies · 311 participants
Very low

Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease

5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).

1 finding from 1 review

Health related quality of life · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASA changes health related quality of life compared with purine antimetabolites (very low certainty).

1 finding from 1 review